Cost-effectiveness of Population Screening for BRCA M Women Compared With Family History–Based Testir

Journal of the National Cancer Institute 107, 380 DOI: 10.1093/jnci/dju380

Citation Report

CITATION	DEDODT

#	Article	IF	CITATIONS
1	Expanded screening for Ashkenazi Jewish women worth it in UK. PharmacoEconomics & Outcomes News, 2014, 718, 20-20.	0.0	0
2	Is It Time to Offer BRCA1 and BRCA2 Testing to All Jewish Women?. Current Oncology, 2015, 22, 233-236.	2.2	16
3	BRCA1/2 Population Screening: Embracing the Benefits. Current Oncology, 2015, 22, 230-231.	2.2	6
4	Survey on Addressing the Information and Support Needs of Jewish Women at Increased Risk for or Diagnosed with Breast Cancer: The Sharsheret Experience. Healthcare (Switzerland), 2015, 3, 324-337.	2.0	7
5	Proposed Shift in Screening for Breast Cancer—Reply. JAMA - Journal of the American Medical Association, 2015, 313, 525.	7.4	3
6	Imaging surveillance programs for women at high breast cancer risk in Europe: Are women from ethnic minority groups adequately included? (Review). International Journal of Oncology, 2015, 47, 817-839.	3.3	6
7	Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation. Molecular Diagnosis and Therapy, 2015, 19, 351-364.	3.8	23
8	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
9	Population-Wide Screening for Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: Too Much of a Good Thing?. Journal of Clinical Oncology, 2015, 33, 3092-3095.	1.6	43
10	Diagnosis of ovarian cancer. BMJ, The, 2015, 351, h4443.	6.0	68
11	Cost-effectiveness of UniversalBRCA1/2Screening. JAMA Oncology, 2015, 1, 1217.	7.1	33
12	Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. Frontiers in Oncology, 2016, 6, 119.	2.8	15
13	Breast Cancer Genetic Counseling: A Surgeon's Perspective. Frontiers in Surgery, 2016, 3, 4.	1.4	11
14			
	Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. Journal of Medical Genetics, 2016, 53, 472-480.	3.2	42
15	Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. Journal of Medical Genetics, 2016, 53, 472-480. Specifying the ovarian cancer risk threshold of â€ [°] premenopausal risk-reducing salpingo-oophorectomyâ€ [™] for ovarian cancer prevention: a cost-effectiveness analysis. Journal of Medical Genetics, 2016, 53, 591-599.	3.2 3.2	42 57
15 16	Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. Journal of Medical Genetics, 2016, 53, 472-480. Specifying the ovarian cancer risk threshold of †premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. Journal of Medical Genetics, 2016, 53, 591-599. The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada. Journal of Genetic Counseling, 2016, 25, 1309-1316.	3.2 3.2 1.6	42 57 24
15 16 17	Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. Journal of Medical Genetics, 2016, 53, 472-480.Specifying the ovarian cancer risk threshold of †premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. Journal of Medical Genetics, 2016, 53, 591-599.The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada. Journal of Genetic Counseling, 2016, 25, 1309-1316.The future of clinical cancer genomics. Seminars in Oncology, 2016, 43, 615-622.	3.23.21.62.2	42 57 24 23

CITATION REPORT

#	Article	IF	CITATIONS
19	Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. The Cochrane Library, 2016, , .	2.8	3
20	Genetic testing and personalized ovarian cancer screening: a survey of public attitudes. BMC Women's Health, 2016, 16, 46.	2.0	29
21	Randomized Noninferiority Trial of Telephone Delivery of <i>BRCA1/2</i> Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up. Journal of Clinical Oncology, 2016, 34, 2914-2924.	1.6	91
22	Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions. Gynecologic Oncology, 2016, 140, 90-94.	1.4	11
23	Genetic Epidemiology and Public Health: The Evolution From Theory to Technology. American Journal of Epidemiology, 2016, 183, 387-393.	3.4	12
24	Crucial considerations for pipelines to validate circulating biomarkers for breast cancer. Expert Review of Proteomics, 2016, 13, 201-211.	3.0	6
25	Genetic screening for gynecological cancer: where are we heading?. Future Oncology, 2016, 12, 207-220.	2.4	11
26	The hallmarks of premalignant conditions: a molecular basis for cancer prevention. Seminars in Oncology, 2016, 43, 22-35.	2.2	27
27	Population genetic testing for cancer susceptibility: founder mutations to genomes. Nature Reviews Clinical Oncology, 2016, 13, 41-54.	27.6	86
28	Hereditary Ovarian Cancer and Risk Reduction. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 31-48.	2.8	40
29	Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Research, 2017, 19, 34.	5.0	64
30	Precision reproductive medicine: multigene panel testing for infertility risk assessment. Journal of Assisted Reproduction and Genetics, 2017, 34, 967-973.	2.5	11
31	Population screening for BRCA1/BRCA2 mutations: lessons from qualitative analysis of the screening experience. Genetics in Medicine, 2017, 19, 628-634.	2.4	25
32	Population-Based Study of Attitudes toward <i>BRCA</i> Genetic Testing among Orthodox Jewish Women. Breast Journal, 2017, 23, 333-337.	1.0	13
33	A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Value in Health, 2017, 20, 567-576.	0.3	54
34	A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer. Value in Health, 2017, 20, 547-555.	0.3	40
35	Use of BRCA Mutation Test in the U.S., 2004–2014. American Journal of Preventive Medicine, 2017, 52, 702-709.	3.0	64
36	Genetic testing for gynaecological cancer. Obstetrics, Gynaecology and Reproductive Medicine, 2017, 27, 29-31.	0.3	0

CITATION REPORT

#	Article	IF	CITATIONS
38	Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. American Journal of Obstetrics and Gynecology, 2017, 217, 578.e1-578.e12.	1.3	63
39	Experiences from a pilot program bringing BRCA1/2 genetic screening to the. Genetics in Medicine, 2017, 19, 529-536.	2.4	16
40	Community attitudes towards a Jewish community BRCA1/2 testing program. Familial Cancer, 2017, 16, 17-28.	1.9	7
41	Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK. BMJ Open, 2017, 7, e017675.	1.9	16
42	Simulation modeling for stratified breast cancer screening – a systematic review of cost and quality of life assumptions. BMC Health Services Research, 2017, 17, 802.	2.2	6
43	BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. ESMO Open, 2018, 3, e000328.	4.5	17
44	Current detection rates and time-to-detection of all identifiable <i>BRCA</i> carriers in the Greater London population. Journal of Medical Genetics, 2018, 55, 538-545.	3.2	45
45	Ovarian Cancer Prevention and Screening. Obstetrics and Gynecology, 2018, 131, 909-927.	2.4	176
46	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. Journal of the National Cancer Institute, 2018, 110, 714-725.	6.3	138
47	Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review. Genetics in Medicine, 2018, 20, 1145-1156.	2.4	28
48	Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. American Journal of Obstetrics and Gynecology, 2018, 218, 431.e1-431.e12.	1.3	32
49	Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. Genetics in Medicine, 2018, 20, 985-994.	2.4	76
50	ls BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia. Applied Health Economics and Health Policy, 2018, 16, 395-406.	2.1	14
51	Medical therapy for preventing recurrent endometriosis after conservative surgery: a costâ€effectiveness analysis. BJOC: an International Journal of Obstetrics and Gynaecology, 2018, 125, 469-477.	2.3	18
52	Germline BRCA mutation in male carriers—ripe for precision oncology?. Prostate Cancer and Prostatic Diseases, 2018, 21, 48-56.	3.9	13
53	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	1.6	155
54	Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation. Revista De Saude Publica, 2018, 52, 94.	1.7	9
55	Understanding Factors Associated with Uptake of <i> BRCA1/2</i> Genetic Testing <i></i> among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach. Public Health Genomics, 2018, 21, 186-196.	1.0	4

		CITATION REPORT		
# 56	ARTICLE Population Based Testing for Primary Prevention: A Systematic Review. Cancers, 2018, 10, 42	ا 4. ٤	F 3.7	CITATIONS
57	TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mut testing in young breast cancer patients. PLoS ONE, 2018, 13, e0209934.	ation 2	2.5	10
58	Population Testing for High Penetrance Genes: Are We There Yet?. Journal of the National Car Institute, 2018, 110, 687-689.	icer é	5.3	6
60	Cancer genetics, precision prevention and a call to action. Nature Genetics, 2018, 50, 1212-1	218. 2	21.4	94
61	A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer. Breast Cancer Research and Treatment, 2018, 172, 637-646.	2	2.5	19
62	Cancer Susceptibility Genetic Testing in a Highâ€Risk Cohort of Urban Ashkenazi Jewish Indiv Journal of Genetic Counseling, 2018, 27, 1405-1410.	duals. 1	L.6	3
63	Pharmacogenomics and Psychiatric Clinical Care. Journal of Psychosocial Nursing and Mental Services, 2018, 56, 22-31.	Health c).6	4
65	Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish bre pedigrees using the BOADICEA model. Familial Cancer, 2019, 18, 381-388.	ast cancer 1	9	8
66	Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endomet and ovarian cancer. Journal of Surgical Oncology, 2019, 120, 864-872.	rial 1	1.7	11
67	Cost-effectiveness of precision medicine: a scoping review. International Journal of Public Hea 2019, 64, 1261-1271.	lth, 2	2.3	55
68	An update on genetic risk assessment and prevention: the role of genetic testing panels in brace cancer. Expert Review of Anticancer Therapy, 2019, 19, 787-801.	east 2	2.4	16
69	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Ea African, and South European countries. Human Mutation, 2019, 40, e1-e23.	stern, North 2	2.5	34
70	Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogen Carriers Missed by Current Genetic TestingÂGuidelines. Journal of Molecular Diagnostics, 201 646-657.	ic Variant 9, 21, 2	2.8	81
71	Attitude towards and factors affecting uptake of populationâ€based <i><scp>BRCA</scp>the Ashkenazi Jewish population: a cohort study. BJOG: an International Journal of Obstetrics Gynaecology, 2019, 126, 784-794.</i>	> testing in and 2	2.3	23
72	A commentary on population genetic testing for primary prevention: changing landscape and to change paradigm. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 120	the need 25, 686-689. 2	2.3	3
73	A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of <i>BRCA1/2</i> . Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 293-302.	2	2.5	6
74	Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genetics in Medicine, 2019, 21, 1958-1968.	; 2	2.4	63
75	Polygenic risk scoring and prediction of mental health outcomes. Current Opinion in Psycholo 2019, 27, 77-81.	ygy,	1.9	25

CITATION REPORT

#	Article	IF	CITATIONS
76	Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. Genetics in Medicine, 2019, 21, 913-922.	2.4	45
77	Evaluating the Cost Effectiveness of a Suicide Prevention Campaign Implemented in Ontario, Canada. Applied Health Economics and Health Policy, 2020, 18, 189-201.	2.1	10
78	Randomised trial of populationâ€based <i><scp>BRCA</scp></i> testing in Ashkenazi Jews: longâ€ŧerm outcomes. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 364-375.	2.3	45
79	Online BRCA1/2 screening in the Australian Jewish community: a qualitative study. Journal of Community Genetics, 2020, 11, 291-302.	1.2	11
80	Knowledge and opinions regarding <i>BRCA1</i> and <i>BRCA2</i> genetic testing among primary care physicians. Journal of Genetic Counseling, 2020, 29, 122-130.	1.6	16
81	Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions. Journal of Clinical Oncology, 2020, 38, 332-350.	1.6	25
82	Current Approaches to Germline Cancer Genetic Testing. Annual Review of Medicine, 2020, 71, 85-102.	12.2	12
83	Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems. Cancers, 2020, 12, 1929.	3.7	49
84	Women's Intentions to Engage in Risk-Reducing Behaviours after Receiving Personal Ovarian Cancer Risk Information: An Experimental Survey Study. Cancers, 2020, 12, 3543.	3.7	5
85	Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops. International Journal of Technology Assessment in Health Care, 2020, 36, 104-112.	0.5	13
86	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. Cancers, 2020, 12, 1241.	3.7	19
87	Population-based Genetic Testing for Precision Prevention. Cancer Prevention Research, 2020, 13, 643-648.	1.5	20
88	Population-based genetic testing for Women's cancer prevention. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 139-153.	2.8	23
89	Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program. Journal of Personalized Medicine, 2020, 10, 7.	2.5	16
90	Population Screening for Inherited Predisposition to Breast and Ovarian Cancer. Annual Review of Genomics and Human Genetics, 2020, 21, 373-412.	6.2	31
91	A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. Cancer Prevention Research, 2020, 13, 429-442.	1.5	10
92	Genetic counselors' perspectives on populationâ€based screening for <i>BRCA</i> â€related hereditary breast and ovarian cancer and Lynch syndrome. Journal of Genetic Counseling, 2021, 30, 158-169.	1.6	8
93	Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis. PLoS ONE, 2021, 16, e0247363.	2.5	14

#	Article	IF	CITATIONS
94	A simple framework to identify optimal costâ€effective risk thresholds for a single screen: Comparison to Decision Curve Analysis. Journal of the Royal Statistical Society Series A: Statistics in Society, 2021, 184, 887.	1.1	3
95	Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paper. BMJ Open, 2021, 11, e041186.	1.9	2
96	Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!. Oncology Reviews, 2021, 15, 544.	1.8	4
97	Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies. European Journal of Health Economics, 2021, 22, 1311-1344.	2.8	18
98	Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations. Hereditary Cancer in Clinical Practice, 2021, 19, 35.	1.5	8
99	Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions. Oncotarget, 2021, 12, 1600-1614.	1.8	14
100	Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 165-175.	2.8	12
101	Population based germline testing for primary cancer prevention. Oncotarget, 2018, 9, 33062-33063.	1.8	4
105	Defining Health-Related Quality of Life in Localized and Advanced Stages of Breast Cancer – the First Step towards Hereditary Cancer Genetic Counseling. Acta Clinica Croatica, 2020, 59, 209-215.	0.2	2
106	Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel. Cancer Prevention Research, 2021, 14, 455-462.	1.5	14
107	A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer. Global & Regional Health Technology Assessment, 2020, 7, 1-8.	0.1	0
108	Jewish cultural and religious factors and uptake of populationâ€based <i>BRCA</i> testing across denominations: a cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 959-968.	2.3	3
109	Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol. Journal of Personalized Medicine, 2021, 11, 1194.	2.5	1
110	Preventive population genomics: The model of BRCA related cancers. Advances in Genetics, 2021, 108, 1-33.	1.8	1
111	A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders. Genetics in Medicine, 2022, 24, 262-288.	2.4	4
112	Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria. Scientific Reports, 2022, 12, 2507.	3.3	8
113	Populationâ€based screening of Uruguayan Ashkenazi Jews for recurrent <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants. Molecular Genetics & Genomic Medicine, 2022, , e1928.	1.2	1
114	Perspectives on Ovarian Cancer 1809 to 2022 and Beyond. Diagnostics, 2022, 12, 791.	2.6	7

ARTICLE IF CITATIONS # Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by TP53 115 2.8 8 p.R337H Carriers. Frontiers in Oncology, 2022, 12, 836937. Do current family history-based genetic testing guidelines contribute to breast cancer health 5.2 9 inequities?. Npj Breast Cancer, 2022, 8, 36. Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative 117 2.6 3 Study Using Semi-Structured Interviews. Diagnostics, 2022, 12, 1028. Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health 2.5 system. Breast Cancer Research and Treatment, 2022, 195, 153-160. Randomised trial of populationâ€based <scp> <i>BRCA</i> </scp> testing in Ashkenazi Jews: longâ€term secondary lifestyle behavioural outcomes. BJOG: an International Journal of Obstetrics and 120 2.3 4 Gynaecology, 2022, 129, 1970-1980. Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome. 3.7 Cancers, 2022, 14, 4717. Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy. International Journal of 122 2.6 17 Environmental Research and Public Health, 2022, 19, 12057. From the patient to the population: Use of genomics for population screening. Frontiers in Genetics, 2.3 0,13,. What happens in the long term: Uptake of cancer surveillance and prevention strategies among atâ€risk 124 4.1 4 relatives with pathogenic variants detected via cascade testing. Cancer, 2022, 128, 4241-4250. A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. Journal 2.1 of Medical Economics, 2023, 26, 19-33. Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi 126 3 3.7 Jews Compared with Family History-Based Strategies. Cancers, 2022, 14, 6113. Cost-Effectiveness of Genetic Testing Strategies for Breast Cancer., 2023, 113-126. BRCA1/2 potential founder variants in the Jordanian population: an opportunity for a customized 128 1.5 0 screening panel. Hereditary Cancer in Clinical Practice, 2023, 21, . Economic evaluations of predictive genetic testing: A scoping review. PLoS ONE, 2023, 18, e0276572. 129 2.5 Population based germline testing of BRCA1, BRCA2 and PALB2 in breast cancer patients in the UK: 130 Evidence to support extended testing and definition of groups who may not require testing., 2023, 1 100849. Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of 2.4 Inherited Predisposition Testing. Genes, 2024, 15, 219. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer. JAMA 132 5.90 Network Open, 2024, 7, e2355324. Screening and prevention of ovarian cancer. Medical Journal of Australia, 2024, 220, 264-274.

CITATION REPORT

		CITATION REPORT	
#	Article	IF	CITATIONS
134	A cost-benefit analysis of genetic screening test for breast cancer in Iran. BMC Cancer, 2024, 24,	. 2.6	0
135	Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review. BMC Cancer, 2024, 24, .	2.6	ο